RTW Investments LP Makes New Investment in CeriBell (NASDAQ:CBLL)

RTW Investments LP bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 150,000 shares of the company's stock, valued at approximately $3,882,000. RTW Investments LP owned 0.42% of CeriBell as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rhumbline Advisers acquired a new position in CeriBell during the fourth quarter valued at $320,000. Corebridge Financial Inc. purchased a new stake in CeriBell during the 4th quarter valued at about $158,000. PNC Financial Services Group Inc. purchased a new position in shares of CeriBell during the fourth quarter worth $47,000. Massachusetts Financial Services Co. MA acquired a new position in CeriBell in the 4th quarter valued at about $10,750,000. Finally, Vanguard Group Inc. acquired a new stake in CeriBell during the 4th quarter worth approximately $18,015,000.

Insider Buying and Selling at CeriBell

In related news, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $16.96, for a total value of $424,000.00. Following the completion of the sale, the chief executive officer now directly owns 727,151 shares in the company, valued at approximately $12,332,480.96. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 49,700 shares of company stock valued at $796,434 in the last 90 days. 20.10% of the stock is currently owned by corporate insiders.

CeriBell Price Performance

CBLL traded down $0.65 on Wednesday, hitting $17.53. 161,796 shares of the company's stock were exchanged, compared to its average volume of 276,336. The stock has a fifty day moving average of $17.36 and a two-hundred day moving average of $22.29. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. As a group, sell-side analysts expect that CeriBell will post -2.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.